Sutent — United Healthcare
gastrointestinal stromal tumor (GIST)
Preferred products
- Gleevec
- Stivarga
- Qinlock
Initial criteria
- Diagnosis of gastrointestinal stromal tumor (GIST)
- AND one of the following:
- History of disease progression on, contraindication, or intolerance to Gleevec (imatinib), Stivarga (regorafenib), or standard dose Qinlock (ripretinib)
- OR SDH-deficient GIST
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Sutent therapy
Approval duration
12 months